ImmunityBio completes NK cell manufacturing programs with 74 subjects
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
March 13, 2026 7:30 AM EDTMethods developed and validated to establish the World Bank of NK Cells from healthy donors and cancer patients Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo) Combination of M-ceNK with ANKTIVA®... More
